| 07/28 | ANALYST RECOMMENDATIONS : Flutter, Hasbro, MGM Resort, Microsoft Vodafone... | |
| 07/27 | MERCK : Truist Assumes Merck & Company at Buy Rating With $92 Price Target | MT |
| 07/14 | MERCK : RBC Lifts Price Target on Merck to $80 From $75 Ahead of Q2 Results, Rei.. | MT |
| 06/09 | MERCK : JPMorgan Adjusts Merck's Price Target to $100 From $105, Maintains Overw.. | MT |
| 06/08 | MERCK : Price Target From RBC Cut to $75 From $77 to Reflect Organon Spinoff, Se.. | MT |
| 06/07 | MERCK : Truist Securities Adjusts Merck's Price Target to $93 From $96, Maintain.. | MT |
| 06/03 | MERCK : SVB Leerink Adjusts Merck & Co.'s Price Target to $99 from $102, Keeps O.. | MT |
| 05/20 | MERCK : Argus Research Downgrades Merck & Company to Hold Rating From Buy | MT |
| 04/30 | MERCK : RBC Capital Adjusts Merck & Company PT to $77 From $79, Maintains Sector.. | MT |
| 2020 | MERCK : Bernstein Reinstates Merck & Co. at Outperform with $95 Price Target | MT |
| 2020 | MERCK : Expects Nearly $2 Billion Covid-19 Revenue Impact in 2020 | DJ |
| 2020 | Pharma Companies Split on Coronavirus Vaccine Pricing Plans | DJ |
| 2020 | MERCK & CO INC : RBC gives a Neutral rating | MD |
| 2019 | Bristol-Myers posts better-than-expected results, Opdivo growth slows | RE |
| 2019 | MERCK & CO INC : Goldman Sachs remains Neutral | MD |
| 2019 | MERCK & CO INC : JP Morgan remains Neutral | MD |
| 2019 | AstraZeneca Imfinzi combination fails advanced lung cancer study | RE |
| 2019 | Elanco to become No.2 in animal health with $7.6 billion Bayer deal | RE |
| 2019 | Elanco to become No.2 in animal health with $7.6 billion Bayer deal | RE |
| 2019 | Eliquis, Orencia sales propel Bristol-Myers to strong second quarter | RE |
| 2019 | Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals | RE |
| 2019 | Merck KGaA clinches $6.5 billion Versum takeover in bet on electrochemicals | RE |
| 2019 | Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value | RE |
| 2018 | Pfizer to replace longtime CEO Read with veteran Bourla | RE |
| 2018 | Pfizer to replace longtime CEO Read with veteran Bourla | RE |
| 2018 | Roche steps up efficiency drive to take sting out of biosimilars | RE |
| 2018 | Roundup cancer verdict sends Bayer shares sliding | RE |
| 2018 | Roundup cancer verdict sends Bayer shares sliding | RE |
| 2018 | Clamour for GSK shingles shot points to bigger profits | RE |
| 2018 | AstraZeneca cancer drug hits second goal by extending survival | RE |
| 2018 | Keytruda sales power Merck to quarterly beat | RE |
| 2018 | Keytruda sales power Merck to quarterly beat | RE |
| 2018 | GlaxoSmithKline prescribes commercial reboot for pharma division | RE |
| 2018 | GlaxoSmithKline prescribes commercial reboot for pharma division | RE |
| 2018 | Bristol-Myers to pay $1.85 billion in cancer deal with Nektar | RE |
| 2018 | U.S. tax change to help Roche's 2018 profit growth outpace sales | RE |
| 2017 | Roche drug cocktail doubles chance of holding lung cancer at bay | RE |
| 2017 | GSK wins U.S. shingles vaccine approval, UK nod for gene therapy | RE |
| 2017 | Germany's Merck hires JP Morgan to sell consumer health | RE |
| 2017 | AstraZeneca shares surge after key drug shows promise in lung cancer trial | RE |
| 2017 | MERCK : 2017 forecast reassuring; full-speed ahead with Keytruda | RE |
| 2017 | Bristol-Myers lung cancer delay slams shares, keeps Merck in lead | RE |
| 2017 | Bristol-Myers shares fall on lung cancer timeline setback | RE |
| 2016 | Pharma, biotech shares soar as Trump win calms pricing talk | RE |
| 2016 | Pharma, biotech shares soar as Trump win calms pricing talk | RE |
| 2016 | Drugmakers under fire for possible U.S. price fixing | RE |
| 2016 | Bristol lung-cancer setback puts rival Merck drug in driver seat | RE |
| 2016 | MERCK : China's drugs watchdog struggles as senior staff lured away by industry | RE |
| 2016 | BRISTOL MYERS SQUIBB : Merck sales disappoint as Januvia, Remicade fall short | RE |
| 2016 | Merck gives cautious 2016 outlook as sales of top medicines lag | RE |
| 2015 | Merck profit tops estimates on strong diabetes, cancer drug sales | RE |
| 2015 | Wall St. ends lower with oil prices, renewed Greece worries | RE |
| 2014 | Pfizer dampens Astra bid hopes with German Merck cancer deal | RE |
| 2014 | AstraZeneca touts independence as Nexium drug keeps on giving | RE |
| 2014 | AstraZeneca gets sales boost as Nexium drug keeps on giving | RE |
| 2014 | Bayer third-quarter adjusted profit gains slightly on strong crop chemicals | RE |
| 2014 | MERCK : quarterly profit beats estimates; shares gain | RE |
| 2014 | Bayer signs $14.2 billion acquisition loan | RE |
| 2014 | Bayer wins Merck & Co's $14 billion consumer unit auction | RE |
| 2014 | Bayer wins Merck & Co's $14 billion consumer unit auction | RE |
| 2014 | EXCLUSIVE : Abbott taps Morgan Stanley to sell mature products - sources | RE |
| 2014 | AstraZeneca cancer pipeline seen as draw for Pfizer | RE |
| 2014 | Reckitt Benckiser sees more sales growth, names chairman for pharma unit | RE |
| 2014 | Trade group seeks more U.S. pressure on India over patent protection | RE |
| 2014 | AstraZeneca profits heading south as patent losses bite | RE |
| 2014 | Ablynx agrees Merck cancer deal worth up to 1.7 billion euros | RE |
| 2013 | GSK cancer vaccine disappoints in melanoma trial | RE |
| 2013 | WALL STREET WEEK AHEAD : Central banks, data to steer investors | RE |
| 2013 | Merck to pay $688 million to settle Enhance lawsuits | RE |
| 2012 | Pfizer plans animal health IPO | RE |
| 2012 | New Amgen CEO must win investors with payouts, deals | RE |
| 2009 | S&P 500 C : Move into defensives helps lift Dow and S&P | RE |
| 2009 | PFIZER : profit beats forecasts | RE |
| 2009 | MERCK AND CO : Wall Street buoyed by home sales, Merck | RE |
| 2008 | MERCK AND CO : Merck, Wyeth shares stumble on drug concerns | RE |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
